- Home
- ARWR
as 05-30-2025 4:00pm EST
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.
| Founded: | 2003 | Country: | United States |
| Employees: | N/A | City: | PASADENA |
| Market Cap: | 1.8B | IPO Year: | 1993 |
| Target Price: | $42.13 | AVG Volume (30 days): | 1.9M |
| Analyst Decision: | Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.14 | EPS Growth: | N/A |
| 52 Week Low/High: | $9.57 - $30.41 | Next Earning Date: | 05-12-2025 |
| Revenue: | $545,209,000 | Revenue Growth: | 1436.97% |
| Revenue Growth (this year): | 4380.43% | Revenue Growth (next year): | 66.56% |
Stock Insider Trading Activity of Arrowhead Pharmaceuticals Inc. (ARWR)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Anzalone Christopher Richard | ARWR | Chief Executive Officer | Apr 9 '25 | Sell | $10.96 | 141,122 | $1,533,336.57 | 3,921,255 | |
| Anzalone Christopher Richard | ARWR | Chief Executive Officer | Mar 13 '25 | Sell | $15.07 | 51,425 | $774,974.75 | 3,921,255 | |
| Anzalone Christopher Richard | ARWR | Chief Executive Officer | Mar 3 '25 | Sell | $17.53 | 300,000 | $5,274,333.67 | 3,921,255 |
Latest Arrowhead Pharmaceuticals Inc. News
ARWR Breaking Stock News: Dive into ARWR Ticker-Specific Updates for Smart Investing
Business Wire
3 days ago
Arrowhead Pharmaceuticals to Participate in June 2025 Investor Conferences
Argus Research
11 days ago
ARWR: Raising target price to $13.00
Zacks Small Cap Research
17 days ago
ARWR: Multiple Value Drivers for Long-Term Growth…
MT Newswires
17 days ago
UBS Adjusts Price Target on Arrowhead Pharmaceuticals to $63 From $71, Maintains Buy Rating
Argus Research
18 days ago
ARWR: Rating decreased to a SELL
MT Newswires
19 days ago
RBC Adjusts Price Target on Arrowhead Pharmaceuticals to $40 From $42, Maintains Outperform Speculative Risk Rating
GuruFocus.com
19 days ago
Arrowhead Pharmaceuticals Inc (ARWR) Q2 2025 Earnings Call Highlights: Strong Financials and ...
MT Newswires
19 days ago
Arrowhead Pharmaceuticals Swings to Fiscal Q2 Earnings; Shares Rise After Hours
Compare ARWR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ARWR Arrowhead Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.